EssilorLuxottica Acquires RetinAI, Maker of AI and Data Management Technology
EssilorLuxottica announced it is acquiring Ikerian AG, a Swiss health technology company operating under the RetinAI brand.
Financial terms of the deal were not disclosed.
RetinAI specializes in artificial intelligence (AI) and data management solutions for eyecare. Through the acquisition, EssilorLuxottica adds RetinAI’s software suite, which harnesses machine learning and computer vision to streamline clinical, research, and pharmaceutical workflows. RetinAI’s AI-driven platforms are designed to deliver actionable insights that empower healthcare professionals with precise, data-backed tools to diagnose and manage vision-threatening conditions more effectively.
RetinAI’s flagship platform, RetinAI Discovery, is both FDA-cleared and CE-marked. The system leverages AI to collect, process, and analyze large-scale retinal images and biomarker datasets—supporting diagnosis and disease monitoring for age-related macular degeneration (AMD), glaucoma, and diabetic retinopathy.
“In the past year alone, we’ve made several bold moves in med-tech, all with the goal of building the most comprehensive, digitally enabled patient journey,” said Francesco Milleri, Chairman and CEO of EssilorLuxottica. “RetinAI will add incredible value to an ecosystem that already includes comprehensive eyecare, advanced diagnostics, therapeutic innovation, and surgical excellence. Leveraging its AI-powered analytics, we can turn clinical data into insights that enable faster, more accurate diagnoses and more effective disease monitoring. We are ushering in a new era of healthcare, and it will be transformative for patients everywhere.”
Beyond the clinic, RetinAI partners with leading pharmaceutical companies and research institutions to provide real-world evidence that accelerates clinical studies and drug development, with the goal of contributing to faster therapeutic advancements and improved patient outcomes.
“Joining EssilorLuxottica marks a defining moment in our journey,” said Carlos Ciller, PhD, Chairman and CEO of RetinAI/Ikerian AG. “This acquisition opens an exciting new chapter for our team and technology. From the start, we’ve believed in the power of data and AI to transform patient care. With EssilorLuxottica’s global reach and deep commitment to innovation, we can now bring that vision to life at an entirely new scale and level of positive impact. Together, we’ll shape how technology drives better healthcare, sharper vision, and improved outcomes for patients.”